Metabolic reprogramming is a fundamental hallmark of cancer, which can be exploited for non-invasive tumor imaging. Deuterium magnetic resonance spectroscopy (2H-MRS) recently emerged as a novel, clinically applicable method of non-invasively monitoring flux from 2H-labeled substrates to metabolic products. However, to date, preclinical studies have been performed in vivo, an endeavor that suffers from low-throughput and potential waste of animal lives, especially in treatment response studies. Here, we demonstrate the ability to quantify metabolism of 2H-MRS probes in live cell suspensions. Our studies will expedite the identification of novel 2H-MRS probes for imaging brain tumors and potentially other cancers.
This abstract and the presentation materials are available to members only; a login is required.